KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

AbCellera Biologics (ABCL) Depreciation Expense (2022 - 2023)

AbCellera Biologics (ABCL) has disclosed Depreciation Expense for 2 consecutive years, with $3.9 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Depreciation Expense rose 39.31% year-over-year to $3.9 million, compared with a TTM value of $12.8 million through Dec 2023, up 41.76%, and an annual FY2024 reading of $12.5 million, down 2.02% over the prior year.
  • Depreciation Expense was $3.9 million for Q4 2023 at AbCellera Biologics, up from $3.1 million in the prior quarter.
  • Across five years, Depreciation Expense topped out at $3.9 million in Q4 2023 and bottomed at $1.4 million in Q1 2022.